Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Merck
Moodys
Medtronic
Boehringer Ingelheim

Last Updated: May 26, 2022

CLINICAL TRIALS PROFILE FOR NORVASC


✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for Norvasc

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00125463 ↗ Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive Patients Unknown status The Japanese Society of Hypertension Phase 3 2001-09-01 The purpose of this study is to compare an angiotensin II receptor antagonist (candesartan cilexetil- Blopress┬«) and a calcium channel blocker (amlodipine besilate- Norvasc┬«/Amlodin┬«) in terms of the incidence of cardiovascular events among high-risk hypertensive patients.
NCT00281580 ↗ Telmisartan (Micardis) and Amlodipine (Norvasc) - Factorial Design Study for the Treatment of Hypertension Completed Boehringer Ingelheim Phase 3 2006-04-01 To demonstrate that Micardis and Norvasc when used together are more effective at lowering blood pre ssure.
NCT00294567 ↗ Azelnidipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients by Serial Volumetric IVUS Analysis(ALPS-J) Completed Japan Heart Foundation Phase 4 2005-12-01 In patients with hypertension who undergo elective PCI, the effects of long-term administration of Calblock (azelnidipine) on plaque volume will be determined quantitatively by 3D-IVUS and compared with those of amlodipine besilate (Norvasc or Amlodin).
NCT00294567 ↗ Azelnidipine Anti-Coronary Atherosclerotic Trial in Hypertensive Patients by Serial Volumetric IVUS Analysis(ALPS-J) Completed Juntendo University Phase 4 2005-12-01 In patients with hypertension who undergo elective PCI, the effects of long-term administration of Calblock (azelnidipine) on plaque volume will be determined quantitatively by 3D-IVUS and compared with those of amlodipine besilate (Norvasc or Amlodin).
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Norvasc

Condition Name

Condition Name for Norvasc
Intervention Trials
Hypertension 29
Healthy 12
Essential Hypertension 2
Type 2 Diabetes 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Norvasc
Intervention Trials
Hypertension 29
Essential Hypertension 3
Myocardial Ischemia 3
Angina Pectoris, Variant 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Norvasc

Trials by Country

Trials by Country for Norvasc
Location Trials
United States 148
United Kingdom 9
Canada 7
China 5
Germany 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Norvasc
Location Trials
Texas 10
North Carolina 7
Florida 7
California 6
Missouri 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Norvasc

Clinical Trial Phase

Clinical Trial Phase for Norvasc
Clinical Trial Phase Trials
Phase 4 18
Phase 3 9
Phase 2 2
[disabled in preview] 15
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Norvasc
Clinical Trial Phase Trials
Completed 46
Unknown status 5
Terminated 2
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Norvasc

Sponsor Name

Sponsor Name for Norvasc
Sponsor Trials
Boehringer Ingelheim 3
Daiichi Sankyo Inc. 3
Daiichi Sankyo, Inc. 3
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Norvasc
Sponsor Trials
Other 62
Industry 40
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Moodys
AstraZeneca
Colorcon
McKinsey
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.